Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
Phase 1 Withdrawn
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
Phase 1 Withdrawn
SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Phase 1 Withdrawn
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
Phase 1 Withdrawn
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
Phase 1 Withdrawn
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
Phase 1 Withdrawn
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Phase 1 Withdrawn
iTRAP
Phase 1 Withdrawn
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 Withdrawn
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
Phase 1 Withdrawn
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems
Phase 1 Withdrawn
A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease
Phase 1 Withdrawn
Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.
Phase 1 Withdrawn
Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Withdrawn
Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC
Phase 1 Withdrawn
Ph Ib/BGJ398/Cervix and Other Solid Tumors
Phase 1 Withdrawn
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Phase 1 Withdrawn
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
Phase 1 Withdrawn
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
Phase 1 Withdrawn
27 enrolled